Picture of Renalytix logo

RENX Renalytix Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m+25.6%
3m+119.63%
6m-62.82%
1yr-61.45%
Volume Change (%)
10d/3m+29.9%
Price vs... (%)
52w High-78%
50d MA+28.33%
200d MA-42.1%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-163%
Return on Equity-150.02%
Operating Margin-1244.64%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Renalytix EPS forecast chart

Profile Summary

Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Directors

    Last Annual
    June 30th, 2023
    Last Interim
    June 30th, 2023
    Incorporated
    March 15th, 2018
    Public Since
    November 6th, 2018
    No. of Employees
    80
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    gb flag iconLondon Stock Exchange
    Shares in Issue
    119,916,187

    RENX Share Price Performance

    Similar to RENX

    Picture of Abingdon Health logo

    Abingdon Health

    gb flag iconLondon Stock Exchange

    Picture of Advanced Medical Solutions logo

    Advanced Medical Solutions

    gb flag iconLondon Stock Exchange

    Picture of Advanced Oncotherapy logo

    Advanced Oncotherapy

    gb flag iconLondon Stock Exchange

    Picture of Angle logo

    Angle

    gb flag iconLondon Stock Exchange

    Picture of Aptamer logo

    Aptamer

    gb flag iconLondon Stock Exchange

    FAQ